Andrew D. Goldberg - 07 Mar 2025 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Director
Signature
/s/ Scott Sieckert, Attorney-in-Fact
Issuer symbol
TARS
Transactions as of
07 Mar 2025
Net transactions value
+$90,230
Form type
4
Filing time
11 Mar 2025, 16:01:34 UTC
Previous filing
25 Jun 2024
Next filing
16 Jun 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARS Common Stock Options Exercise $90,230 +7,000 +110% $12.89 13,350 07 Mar 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Stock Option (right to buy) Options Exercise $0 -7,000 -100% $0.000000 0 07 Mar 2025 Common Stock 7,000 $12.89 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The option vested in full on the one-year anniversary of the date of grant.